AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Cell Therapies & Oncolytic Virus Markets, 2016-2019 & 2026 - Stimulation of the Intrinsic Vascular Cell to Provide Ample Industry Opportunities - ResearchAndMarkets.com

November 20, 2019

DUBLIN--(BUSINESS WIRE)--Nov 20, 2019--

The “Global Cell Therapies & Oncolytic Virus Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

The Global Cell Therapies & Oncolytic Virus market is growing at a CAGR of 17.32% from 2018 to 2026.

Factors such as rise in technological advancements and increase in usage of combination therapies are driving the market growth. Though, occurrence of immune reaction to the virus-based treatments caused by repeated administration of therapeutics to treat cancer and Staggering expense related to oncolytic virus therapy are projected to inhibit the growth of the market. Moreover, stimulation of the intrinsic vascular cell may provide ample opportunities for the market growth.

By application, melanoma segment acquired significant growth in the market because most of the cancer therapies are developed for melanoma cancers. Increasing prostate cancer cases are also leading to the strong growth rate in prostate cancer therapies in recent years which is driving the market growth.

The key vendors mentioned are PsiOxus Therapeutics, Cold Genesys, TILT Biotherapeutics, SillaJen Biotherapeutics, Genelux Corporation, Vyriad, Lokon Pharma, TILT Biotherapeutics and Sorrento Therapeutics.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Cell Therapies & Oncolytic Virus Market, By Type

5.1 Introduction

5.2 Adenoviruses-Based Oncolytic viruses

5.3 HSV-Based Oncolytic Viruses

5.4 Newcastle Disease Virus-Based Oncolytic Viruses

5.5 Vaccinia Virus-Based Oncolytic Viruses

5.6 Vesicular Stomatitis Virus-Based Oncolytic Viruses

6 Global Cell Therapies & Oncolytic Virus Market, By Application

6.1 Introduction

6.2 Breast Cancer

6.3 Melanoma

6.4 Ovarian Cancer

6.5 Prostate cancer

7 Global Cell Therapies & Oncolytic Virus Market, By Geography

7.1 Introduction

7.2 North America

7.3 Europe

7.4 Asia-Pacific

7.5 South America

7.6 Middle East & Africa

8 Strategic Benchmarking

9 Vendors Landscape

9.1 PsiOxus Therapeutics

9.2 Cold Genesys

9.3 TILT Biotherapeutics

9.4 SillaJen Biotherapeutics

9.5 Genelux Corporation

9.6 Vyriad

9.7 Lokon Pharma

9.8 TILT Biotherapeutics

9.9 Sorrento Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/sbxykh

View source version on businesswire.com:https://www.businesswire.com/news/home/20191120005880/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/20/2019 02:30 PM/DISC: 11/20/2019 02:30 PM

http://www.businesswire.com/news/home/20191120005880/en